Related references
Note: Only part of the references are listed.Proteoglycan form and function: A comprehensive nomenclature of proteoglycans
Renato V. Iozzo et al.
MATRIX BIOLOGY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts
Moon Fenton et al.
ONCOLOGY RESEARCH (2015)
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
Nobuhiro Nishio et al.
CANCER RESEARCH (2014)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Claudia Geldres et al.
CLINICAL CANCER RESEARCH (2014)
CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA
Federica Riccardo et al.
CLINICAL CANCER RESEARCH (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients
Rolf Warta et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Novel Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy to Eradicate Both Differentiated Cancer Cells and Cancer-Initiating Cells in Solid Tumors
Francesco Sabbatino et al.
SEMINARS IN ONCOLOGY (2014)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Rachel E. Beard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer
Nicholas C. Hsu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Rachel E. Beard et al.
CLINICAL CANCER RESEARCH (2013)
Recombinant production of proteoglycans and their bioactive domains
Megan S. Lord et al.
FEBS JOURNAL (2013)
Human Glioma-Initiating Cells Show a Distinct Immature Phenotype Resembling but Not Identical to NG2 Glia
Alonso Barrantes-Freer et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Diversified Expression of NG2/CSPG4 Isoforms in Glioblastoma and Human Foetal Brain Identifies Pericyte Subsets
Francesco Girolamo et al.
PLOS ONE (2013)
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
Aurelie Poli et al.
ONCOTARGET (2013)
The integration of T cell migration, differentiation and function
David Masopust et al.
NATURE REVIEWS IMMUNOLOGY (2013)
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Zeyana Rivera et al.
CLINICAL CANCER RESEARCH (2012)
Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots
Ziv Shulman et al.
NATURE IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
Agnete Svendsen et al.
ACTA NEUROPATHOLOGICA (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
Xinhui Wang et al.
CANCER RESEARCH (2011)
Targeting ALDHbright Human Carcinoma-Initiating Cells with ALDH1A1-Specific CD8+ T Cells
Carmen Visus et al.
CLINICAL CANCER RESEARCH (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
Hitoe Torisu-Itakura et al.
JOURNAL OF IMMUNOTHERAPY (2011)
NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature
M. Talal F. Al-Mayhani et al.
NEURO-ONCOLOGY (2011)
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
Matthew A. Price et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
Jian Wang et al.
PLOS ONE (2011)
A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
William R. Burns et al.
CANCER RESEARCH (2010)
Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
Michael Campoli et al.
CLINICAL CANCER RESEARCH (2010)
CSPG4 in Cancer: Multiple Roles
X. Wang et al.
CURRENT MOLECULAR MEDICINE (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Xinhui Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Juan F. Vera et al.
CURRENT GENE THERAPY (2009)
The promise and potential pitfalls of chimeric antigen receptors
Michel Sadelain et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: Are We Nearly There Yet?''
Gianpietro Dotti et al.
HUMAN GENE THERAPY (2009)
NG2 Expression Predicts the Metastasis Formation in Soft-Tissue Sarcoma Patients
Maria Serena Benassi et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2009)
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
LEUKEMIA & LYMPHOMA (2009)
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature
Paulo Cesar Maciag et al.
CANCER RESEARCH (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
M. Chekenya et al.
ONCOGENE (2008)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
M. Campoli et al.
ONCOGENE (2008)
A role for the NG2 proteoglycan in glioma progression
William B. Stallcup et al.
CELL ADHESION & MIGRATION (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1
Amanda M. de Mestre et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Differential phosphorylation of NG2 proteoglycan by ERK and PKCα helps balance cell proliferation and migration
Irwan T. Makagiansar et al.
JOURNAL OF CELL BIOLOGY (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2006)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
JB Yang et al.
JOURNAL OF CELL BIOLOGY (2004)
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells
I Rajantie et al.
BLOOD (2004)
Sulfotransferases in glycosaminoglycan biosynthesis
M Kusche-Gullberg et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2003)
Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia:: close association with MLL rearrangement and a CD10-/CD24-/CD65s+/CD15+ B-cell phenotype
S Schwartz et al.
LEUKEMIA (2003)
Plastic casting of embryonic, placental, and tumor vasculature in the mouse
U Ozerdem et al.
MICROVASCULAR RESEARCH (2002)
The NG2 proteoglycan: Past insights and future prospects
WB Stallcup
JOURNAL OF NEUROCYTOLOGY (2002)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis
U Ozerdem et al.
DEVELOPMENTAL DYNAMICS (2001)
Share Paper
